GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Current Accrued Expense

Nexalin Technology (Nexalin Technology) Current Accrued Expense : $0.21 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Current Accrued Expense?

Nexalin Technology's Current Accrued Expense for the quarter that ended in Mar. 2024 was $0.21 Mil.

Nexalin Technology's quarterly Current Accrued Expense declined from Sep. 2023 ($0.61 Mil) to Dec. 2023 ($0.11 Mil) but then increased from Dec. 2023 ($0.11 Mil) to Mar. 2024 ($0.21 Mil).

Nexalin Technology's annual Current Accrued Expense declined from Dec. 2021 ($0.61 Mil) to Dec. 2022 ($0.54 Mil) and declined from Dec. 2022 ($0.54 Mil) to Dec. 2023 ($0.11 Mil).


Nexalin Technology Current Accrued Expense Historical Data

The historical data trend for Nexalin Technology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Current Accrued Expense Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
0.52 0.61 0.54 0.11

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.60 0.61 0.11 0.21

Nexalin Technology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Nexalin Technology Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexalin Technology (Nexalin Technology) Business Description

Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Executives
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology Provides 2022 Year-End Business Update

By sperokesalga sperokesalga 03-27-2023

Nexalin Technology CEO Provides Letter to Shareholders

By Stock market mentor Stock market mentor 01-05-2023